Pegylated interferon-α2a in cutaneous T-cell lymphoma

• Verfasst von: Hansen-Abeck, Inga [VerfasserIn]
• Verfasst von: Geidel, Glenn [VerfasserIn]
• Verfasst von: Abeck, Finn Frederik [VerfasserIn]
• Verfasst von: Kött, Julian [VerfasserIn]
• Verfasst von: Cankaya, Rohat [VerfasserIn]
• Verfasst von: Dobos, Gábor [VerfasserIn]
• Verfasst von: Mitteldorf, Christina [VerfasserIn]
• Verfasst von: Nicolay, Jan Peter [VerfasserIn]
• Verfasst von: Albrecht, Jana Dorothea [VerfasserIn]
• Verfasst von: Menzer, Christian [VerfasserIn]
• Verfasst von: Livingstone, Elisabeth [VerfasserIn]
• Verfasst von: Mengoni, Miriam [VerfasserIn]
• Verfasst von: Braun, Andreas [VerfasserIn]
• Verfasst von: Wobser, Marion [VerfasserIn]
• Verfasst von: Klemke, Claus-Detlev [VerfasserIn]
• Verfasst von: Tratzmiller, Sabine [VerfasserIn]
• Verfasst von: Assaf, Chalid [VerfasserIn]
• Verfasst von: Terheyden, Patrick [VerfasserIn]
• Verfasst von: Klespe, Kai-Christian [VerfasserIn]
• Verfasst von: Schneider, Stefan W. [VerfasserIn]
• Verfasst von: Booken, Nina [VerfasserIn]
• Titel: Pegylated interferon-α2a in cutaneous T-cell lymphoma
• Titelzusatz: a multicenter retrospective data analysis with 70 patients
• Verf.angabe: Inga Hansen-Abeck, Glenn Geidel, Finn Abeck, Julian Kött, Rohat Cankaya, Gabor Dobos, Christina Mitteldorf, Jan P. Nicolay, Jana D. Albrecht, Christian Menzer, Elisabeth Livingstone, Miriam Mengoni, Andreas D. Braun, Marion Wobser, Claus-Detlev Klemke, Sabine Tratzmiller, Chalid Assaf, Patrick Terheyden, Kai-Christian Klespe, Stefan W. Schneider, Nina Booken
• E-Jahr: 2024
• Jahr: November 2024
• Umfang: 9 S.
• Fussnoten: Erstmals veröffentlicht: 02. Oktober 2024 ; Gesehen am 07.01.2025
• Titel Quelle: Enthalten in: Deutsche Dermatologische GesellschaftJournal der Deutschen Dermatologischen Gesellschaft
• Ort Quelle: Berlin : Wiley-Blackwell, 2003
• Jahr Quelle: 2024
• Band/Heft Quelle: 22(2024), 11, Seite 1489-1497
• ISSN Quelle: 1610-0387
• DOI: doi:10.1111/ddg.15511
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: cutaneous t-cell lymphomas
• Sach-SW: interferon-alpha
• Sach-SW: Mycosis fungoides
• Sach-SW: pegylated interferon
• Sach-SW: Sézary Syndrome
• K10plus-PPN: 1912810360

Abstract

Background Interferon-alpha is an important therapeutic option for the treatment of the cutaneous T-cell lymphomas (CTCL). Since the approved recombinant interferon-α-2a (IFN-α2a) has no longer been produced since January 2020, pegylated interferon-α2a (pegIFN-α2a) can be used as an alternative treatment, even though it is not approved for the treatment of CTCL. The aim of this multicentre study was to generate comprehensive data on the efficacy and tolerability of pegIFN-α2a in the treatment of CTCL. Patients and Methods A multicenter retrospective study was conducted with 70 patients with CTCL from twelve German skin centers. Results In total, 70 patients were included in the study, with 57.2% male and a mean age of 58.8 ± 14.9 years. Mycosis fungoides was present in 71.4% of cases and Sézary Syndrome in 28.6%. An overall response rate of 55.2% was observed with pegIFNα-2a therapy. In 50% of cases, therapy was discontinued after 63.6 ± 33.5 weeks. The most common reason for discontinuation was adverse events, which occurred in 68.6% of cases and which were classified as severe in 29.2%. Blood count changes, fatigue and liver toxicity occurred most frequently. Conclusions Our analysis provides comprehensive data on the efficacy and tolerability of pegIFNα-2a therapy in patients with CTCL. In terms of response rates and side effect profile, pegIFNα-2a appears to be comparable to IFN-α2a therapy.